# Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

> **NCT03217747** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 173 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Castration-Resistant Prostate Carcinoma
- Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Metastatic Prostate Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- Refractory Malignant Solid Neoplasm
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Avelumab
- **BIOLOGICAL:** Ivuxolimab
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Utomilumab

## Key facts

- **NCT ID:** NCT03217747
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-02
- **Primary completion:** 2025-09-02
- **Final completion:** 2026-04-30
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03217747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03217747, "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03217747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*